{
    "pmcid": "9822811",
    "qa_pairs": {
        "What is the mechanism by which the biparatopic antibody neutralizes the virus, according to the summary?": [
            "Steric hindrance preventing spike protein engagement with ACE2",
            "Direct blocking of the ACE2 binding site",
            "Inducing conformational changes in the spike protein",
            "Cleaving the spike protein"
        ],
        "What is the primary target for neutralizing antibodies in SARS-CoV-2, as mentioned in the summary?": [
            "The receptor-binding domain (RBD) of the spike protein",
            "The nucleocapsid protein",
            "The membrane protein",
            "The envelope protein"
        ],
        "What technology was used to engineer the biparatopic antibody BA7208/7125?": [
            "Knobs-into-holes technology",
            "CRISPR-Cas9 technology",
            "Zinc finger nuclease technology",
            "TALEN technology"
        ],
        "Which administration routes were tested for BA7208/7125 in vivo studies?": [
            "Intraperitoneal, intranasal, and aerosol inhalation",
            "Oral, intravenous, and subcutaneous",
            "Topical, transdermal, and intramuscular",
            "Rectal, buccal, and sublingual"
        ],
        "Which mutation in the Mu variant likely reduces the effectiveness of BA7208?": [
            "R346K mutation",
            "N501Y mutation",
            "D614G mutation",
            "E484K mutation"
        ]
    }
}